Recombinant Biotinylated SARS-CoV-2 Spike RBD Protein, His,Avitag™ (BA.2/Omicron) (MALS verified), 25 µg

Background
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant Biotinylated SARS-CoV-2 Spike RBD, His,Avitag (BA.2/Omicron) (SPD-C82Eq) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1 (G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H)). The spike mutations are identified on the SARS-CoV-2 Omicron variant (Pango lineage: BA.2; GISAID clade: GRA; Nextstrain clade: 21L).
Predicted N-terminus: Arg 319

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 28.4 kDa. The protein migrates as 35-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20 to -70°C for 12 months in lyophilized state from date of receipt;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2"
Maeda, Toyoda, Kuwata et al
Int J Mol Sci (2024) 25 (2)
(2) "Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine"
Muranishi, Kinoshita, Inoue et al
Vaccines (Basel) (2023) 12 (1)
(3) "Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers"
Matula, Bekő, Király et al
Vaccines (Basel) (2023) 12 (1)
Showing 1-3 of 4353 papers.